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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not daily
supplementation with omega-3 fatty acids is effective in reducing the severity of dry eyes in
adult patients with dry eyes syndrome (DES).
Methods: Three randomized controlled trials are included in this review that were published in
2013, 2016 and 2017.
Data sources: The author of this paper performed the research as well as selected the articles for
review by conducting searches on PubMed, Embase and Cochrane Library.
Outcomes: The outcome measured is the severity of dry eyes symptoms measured subjectively
by each patient through a 12-item questionnaire after a minimum of one month and maximum 12
weeks of treatment. The Ocular Surface Disease Index (OSDI), (Allergan, Inc.), scale was used
to measure subjective outcomes in all studies. An average score for each group was calculated as
well as the change in scores between the first and the last day of studies.1,2,3
Results: In Deinema et al (2017), for patients taking krill oil supplementation, dry eye
symptoms improved 18.6+/-2.4 points (mean change in baseline score) over three months per
OSDI scores.1 In Epitropoulo et al (2016), in the treatment group symptoms improved 17.0+/-2.6
points over three months.2 In Kangari et al (2013), symptoms improved 9.4+/-0.6 points over one
month patients receiving treatment while the placebo group reported a 1.2+/-0.3 point worsening
of symptoms.3 All data described above was statistically significant (p < 0.005).
Conclusions: It can be concluded that daily omega-3 essential fatty acid supplementation is
effective for reducing the severity of dry eye syndrome in adults, especially those with mildmoderate DES after 90 days.
Key Words: Dry eye syndrome; Omega-3 fatty acids
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INTRODUCTION
Dry eyes are a manifestation of a disorder that is best known as dry eye disease (DED)1,
meibomian gland dysfunction (MGD)2 or dry eye syndrome (DES)3. This is a multifactorial
disease of the lacrimal gland that involves an inflammatory response at the ocular surface with
debilitating irritation as well as profound visual impairment.4 It occurs when the eye is not
properly lubricated with tears as a result of either poor production, excessive evaporation or
improperly balanced components.4
This systematic review paper evaluates three randomized clinical trials (RCT’s) in order to
compare the efficacy of daily supplementation with oral omega-3 (ω-3) fatty acids for reducing
the severity of dry eyes in adult patients with DES. Earlier studies reported that intake of ω-3
fatty acids, through dietary consumption of fish or by oral supplementation, have antiinflammatory effects within the body. This was first seen by a reduction of autoimmune disease
incidence, and later on for the benefit of other disorders like DES.5 Current research suggests that
omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) block proinflammatory mediators at the surface of the eye while providing symptomatic relief.1,2,3
Healthy eyes require protection from multiple layers of tears in order to function properly.6
First, a lipid layer helps spread the tear film evenly over the surface. Next, an aqueous protein
layer nourishes the cornea. Lastly, a mucous layer provides continuous lubrication.6 DES
involves either the decreased production of tears (aqueous-deficiency) or increased evaporative
loss, however it is usually a mixture of both.4 In deficiency, tears fail to be made and cannot
complete lubrication. In evaporation, tears are lost and abnormal lipids levels exist.4,6 In either
type, increased osmolarity of the tear film results in release of pro-inflammatory cytokines (IL-1,
IL-6 and TNF-α),1 which activates sensory nerves and triggers dry eye symptoms.6 The poor
quality of tears focuses light improperly on the retina and blurs the vision reversibly.6 Most
patients suffer mild to moderate discomfort chronically.
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An estimated 14.5% of adults in the United States suffer from dry eyes, including 17.9% of
women and 10.5% of men affected.7 Up to 30% of Americans over the age of 50 are reportedly
affected and the prevalence is expected to increase with the aging population.7 Post menopausal
women are especially at risk due to changes in hormone levels.5 In addition, DES is now
affecting younger generations due to constant computer use that reduces the frequency of
blinking.4,6 Other risk factors include contact lens (CL) use, low humidity environments,
previous eye surgery, presence of systemic disease and certain medications4,6 All of these factors
have been known to reduce the quality and quantity of tears.6
It’s estimated that the annual cost of managing dry eye in the U.S is $55 billion.8 No data
is available on the number of healthcare visits for dry eyes annually. However, it is stated to be
the most common reason for seeking eye care.7 Most patients present with non-specific irritative
symptoms such as burning, pruritus, foreign body sensations, excessive tearing, blurry vision,
photophobia and redness.6,7 Other complaints relate to vision impairment and include difficulty
reading, driving or performing daily activities.4 Ultimately, quality of life can be significantly
reduced in DES to a degree that has been reported to be equivalent to angina pectoris.7
Artificial tears (AT’s), available over-the-counter, are the mainstay of treatment.6 They
enhance the viscosity of tears and provide only short-term relief from irritation without
addressing inflammation.4,6 Warm compresses are an option for extra support.4 First line medical
therapies includes topical immunosuppressant drugs that reverse the inflammatory mechanism.4,6
This includes Restasis® (cyclosporine emulsion) 0.05%, cytokine activation inhibitor and
Xiidra® (lifitegrast solution) 5%, an integrin antagonist.4,6 Both products are expensive without
insurance but can potentially offer long-term relief.4,6,7 Ultimately, for most patients, there is no
permanent solution and treatment is long-term with a combination of methods.4,6,7
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Omega-3 is a polyunsaturated fat essential for normal growth and development of the
human body.4,9 Benefits in the eye include increased levels of fatty acids in secretions, which
improves tear film quality and prevent evaporation, thus reducing DES symptoms.4,6 When
digested omega-3 favors anti-inflammatory pathways via the blockade of cytokines and
competitively inhibits pro-inflammatory pathways.1,2,7 Consuming cold-water fish (salmon, tuna
and sardines) with high amounts of ω-3 helps raise levels in the body.9 However, fish have high
mercury levels as well as other toxins and cannot be consumed in quantities that would benefit
the eye without causing other health risks.1,9
This method of treatment is being proposed because omega-3 supplements are marketed
for and recommended by practitioners for DES but research has been inconsistent. Omega-3 is
best absorbed by the human body in its natural triglyceride form, however, during manufacturing
it gets converted into an ethyl ester via distillation, which is necessary for toxin elimination. 1,9
Most omega-3 products are available in this poorly absorbed formula. Newer re-esterified
formulas have been converted back into a triglyceride for better absorption. 2,9 In addition, it has
been suggested that phospholipid form, as in krill oil, has even greater bioavailability. This paper
will compare the three different types of omega-3 by measuring patient reported symptoms.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not daily
supplementation with oral omega-3 fatty acids is effective in reducing the severity of dry eye
symptoms in adult patients with clinically diagnosed DES. It is hypothesized that daily intake is
associated with an improvement in symptoms and result in a better quality of life.
METHOD
Three randomized controlled trials (double-blind, placebo-controlled) are reviewed in this
paper that focused on a population of adult patients (18 -90 years old) with a history of DES. The
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intervention of choice is daily oral supplementation with ω-3 fatty acids containing
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The experimental groups
received ω-3 fatty acids and are compared to the control groups who received a visually matched
placebo. Outcome measured is the severity of dry eyes symptoms measured subjectively by each
patient through a 12-item questionnaire, after a minimum of one month and maximum 12 weeks
of treatment. Physical discomfort, visual impairment or environmental triggers were inquired
about in the assessements.1,2,3
The author of this paper performed the research as well as selected the articles for review
by conducting searches on PubMed and Cochrane Library. Each of the three articles had been
published data in peer-reviewed journals in the English language. The search criteria included
‘Dry eye syndrome’ & ‘Omega-3 fatty acids’ as keywords. When selecting studies, the inclusion
criteria consisted of studies that were RCT’s published between 2006 and 2016, studies that used
a regimen of EPA and DHA omega-3 fatty acids in the experimental group and studies that used
the OSDI questionnaire. Exclusion criteria were studies with participants under the age of 18,
studies that allowed use of other therapies, and studies specific to CL use, computers or diseases.
In each study, statistics were reported as the mean change in score (OSDI scale) from baseline at
day one +/- standard error the mean (SEM), as well as in p-value for statistical significance
(p<0.05).1,2,3 Treatment safety was based on the number of reported adverse events.
Study

Type

Deinema,
20171

RCT

#
Pts
60

Table 1: Demographics & Characteristics of Included Studies
Age
Inclusion
Exclusion Criteria
(yrs)
Criteria
≥18
Mild-toCo-morbid ocular pathology;
moderate dry
Uncontrolled systemic disease;
eye symptoms
Systemic disease contraindicating
(OSDI score:
omega-3 supplements; Allergy to
18-65); Tear
fish/seafood, nuts, oil or gelatin; Current
osmolarity of
use of oral ω-3 supplements; Contact
≥316 mOsm/L
lens use within one month or intended
in at least one
use over course of study; History of
eye; IOP <21
ocular surgery or trauma; Active ocular
OU; BCVA
infection or allergy; Use of topical
≥20/40 OU
ocular medications (steroids, NSAIDs,
or cyclosporine) and systemic anticoagulants in the 3 prior months; Use of

W/D

Interventions

6

5 capsules/day
for 3 months of
either:
a) Krill oil: 945
mg/day EPA &
510 mg/day
DHA.
OR
b) Fish oil: 1000
mg/day EPA &
500 mg/day
DHA. Total
1500mg daily.
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any prescription or supplement that
affect tear production or vision.
Epitropoul RCT
122
21-86
MGD stage
MGD stage 3; Use of topical
17
4 softgels/day
os, 20162
(>18)
1,2; Tear
cyclosporine 0.05%, corticosteroids,
for 12 weeks:
osmolarity of
NSAIDs, glaucoma medication, or oral
1680 mg/day
≥312 mOsm/L
ω-3 fatty acids within 3 weeks of
EPA & 560
in at least one
screening; (+) History of refractive
mg/day DHA
eye on 2 visits
surgery within 1 year; Use of systemic
(re-esterified).
medication that affects ocular surface.
Total 2240mg.
Kangari,
RCT
73
45-90
TBUT <10
Active allergies or infection at ocular
9
2 capsules/day
20133
seconds in both surface; Presence of pterygium or
(AM & PM) for
eyes; No use of pinguecula; Use of topical steroidal,
1 month: 360
artificial tears
NSAID, glaucoma, or anti-allergy eye
mg/day EPA &
for past 3
drop in past month; (+) History of
240 mg/day
months
refractive surgery, contact lens use,
DHA. Total
blood/coagulation disorder, gastric
600mg daily.
ulcer, or fish oil/gelatin allergy; Use of
medication that interferes with tear
production; (+) History of any surgery
or use of ω-3 supplements in past 3
months; Currently undergoing
head/neck radiotherapy.
Abbreviations: Ocular Surface Disease Index (OSDI); Meibomian gland dysfunction (MGD); Tear breakup time (TBUT);
Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA); Non-steroidal anti-inflammatory drug (NSAID)

OUTCOMES
The Ocular Surface Disease Index (OSDI), (Allergan, Inc.), scale was used to measure
subjective outcomes in all studies. This is a validated 12-item survey that ranks symptoms using
a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half the time, 3 = most of the
time, 4 = all of the time). Each patient completed a questionnaire at every follow-up. The total
score range is from 0 (none, no disability) to 100 (maximum, full disability) with higher values
representing greater disability. It was important to calculate each subject’s average score per
session as well as the change in scores between the first and the last day of studies.1,2,3
RESULTS
This paper investigates three randomized controlled trials (RCT’s) that assessed the
efficacy of ω-3 fatty acid supplementation in the treatment of DES. Methods of data collection as
well as inclusion and exclusion criteria are discussed above (see Table 1). All three studies
randomized their subjects to either control or experimental treatments group(s), assignments to
which the participants, clinicians and investigators were blind during allocation and throughout
the studies. All three studies used a placebo that was visually comparable to the treatment
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received by experimental group(s). Although the specific placebo varied among each study, ω-3
regimens were also different. Treatment efficacy from all three studies was reported as
continuous data that could not be converted to dichotomous data.1,2,3 Treatment safety is reported
as numbers needed to harm (NNH) and was converted into dichotomous format.
All three studies used the OSDI for symptom assessment as well as patients previously
diagnosed with DES, which was of mild to moderate severity in Deinema et al (2017) and
Epitropoulo et al (2016). In addition all groups in each study had similar OSDI scores at
baseline. All three papers concluded that ω-3 does reduce the severity of DES symptoms,
specific parameters are described below (table 2).1,2,3
Study

Duration

Deinema,
20171
Epitropoulos,
20162
Kangari,
20133

90 days
90 days
30 days
30 days

Table 2: Outcomes of Included Studies
# Participants
Significant
Mean
(n)
Intervention
change from
baseline
score (scale
of 100)
54
Krill oil
-18.6+/-2.4
(1500mg/day)
105
Re-esterified
-17.0+/-2.6
(2240mg/day)
64
DHA & EPA
-9.4+/-0.6
(600mg/day)
64
Placebo
+1.2+/-0.3

p-value

95% CI

p = 0.02

N/A

p = 0.002

-12.0 (-19.4 to -4.5)

P = 0.004

N/A

P = 0.049

Note: symptoms worsened

Deinema et al (2017), is a double-masked, placebo-controlled study (table 3). It enrolled
60 adult patients that were randomly assigned to one of three groups. Assessments occurred in
four visits over 90 days for the 54 that completed the study. EPA/DHA is a phospholipid in krill
oil and is a triglyceride in fish oil, the later being studied more frequently. The placebo was a
1500mg dose of oleic acid (olive oil). While CL use was forbidden, AT use was permitted
throughout the study. In addition, subjects were asked about dietary changes at each visit. The
outcome measured was dry eye symptoms severity on the OSDI scale. Factors affecting the
outcome include the small size of participants (n=54), recruitment from only one treatment
center, high 1500mg dosing, and type of lipid received by participants.
In patients taking krill oil supplementation, dry eye symptoms improved 18.6 points over
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three months as measured by OSDI scores. Meanwhile the placebo group reported a 10.5+/-3.3
point improvement. This represents a reduction from baseline, in other words, an improvement
of symptoms for the krill oil group (mean change in baseline score = -18.6+/-2.4, p = 0.02).
Compared to placebo, only the krill oil group score was statistically significant at day 90
relative to day 1. The outcome was not significant and therefore not reported for fish oil. This
means that ω-3 in phospholipid form of krill oil may offer superior benefits for DES symptoms
compared to triglyceride form of fish oil. Outcomes were not significant for any group at the 2nd
or 3rd follow-up and not reported.1 However, data trends showed improvements for each
throughout the study, suggesting greater outcome with longer duration of therapy.
Table 3: Treatment Effect in Deinema et al (2017)1 (Scores at day 30,60, 90 not reported)
Baseline
Mean change from baseline +/- SEM (scale of 100)
Krill Oil (n=18)
30.5 +/- 2.4
-18.6+/-2.4, p=0.02
Fish Oil (n=19
36 +/- 3.4
Not reported
Placebo (n=17)
31.7 +/- 2.6
-10.5 +/-3.3

Epitropoulo et al (2016), is a multi-centered, double-masked, placebo-controlled study
(table 4) that enrolled 122 adult patients that were randomly assigned to group 1 or 2. For the
105 participants that completed the study, assessments took place in 3 visits over 90 days. The
EPA/DHA provided was in re-esterified form. The placebo was a dose of linoleic acid (safflower
oil), a ω-6 fatty acid. CL and AT use was allowed except before visits for 12 and 2 hours,
respectively. Subjects kept daily food diaries and dietary changes were not allowed. The
outcome was dry eye symptoms severity on the OSDI scale. Factors affecting the outcome
include the use of re-esterified ω-3, the female majority of participants, high dosing with 2240mg
daily. In addition, the choice of ω-6 as a placebo could worsen inflammation as it has been
shown to have this effect in the body, which is opposite to that of omega-3.
In the experimental group, dry eye symptoms improved 17 points over three months as
measured by OSDI scores. Meanwhile the control group had only 5.0+/-2.7 point improvement.
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These values represent a reduction from baseline, in other words, an improvement of symptoms
with treatment (mean change in baseline score = -17.0+/-2.6, p = 0.002, CI = -19.4 to -4.5).
Compared to the control, the score of the treatment group was statistically significant at
12 weeks relative to day 1. This means that the re-esterified omega-3 benefits DES symptoms,
although it is uncertain whether it is superior to the usual triglyceride form. Outcomes were not
significant at 6-weeks, although both groups had less symptoms at this visit.2
Table 4: Treatment Effect in Epitropoulo et al (2016)2 Mean change from baseline +/- SEM (scale of 100)
Baseline
6 weeks
Mean Change
95% CI
12 weeks
Mean Change
95% CI
Omega-3 32.4+/-19.2 21.0+/-14.4
-11.4+/-2.6
-4.0(-11.2
15.5+/-11.0
-17.0+/-2.6
-12.0 (-19.4 to (n=54)
to 3.3);
4.5); p=0.002
p=0.285
Placebo
27.1+/-22.9 19.6+/-17.0
-7.4+/-2.6
22.0+/-19.3
-5.0+/-2.7
(n=51)

Kangari et al (2013), is a double-masked, placebo-controlled study (table 5). It randomly
assigned 73 patients, ages 45-90, to group 1 or 2. Only 64 completed the study and attended each
of two visits within one month. The specific type of EPA/DHA provided was not reported. The
placebo was a medium chain triglyceride. CL and AT use was forbidden throughout the study.
The outcome measured was dry eye symptom severity, on the OSDI scale, at day 30. Factors
affecting the study outcome include the small number of participants (n=64), recruitment from
only one center, small dosing of 600mg/day, the short study duration compared to others, lack of
dietary control over the subjects, and older ages of patients who are at higher risk for DES. The
paper did not mention criteria for disease severity during enrollment.
In the treatment group, dry eye symptoms improved 9.4 points over three months as
measured by OSDI scores. This represents a reduction from baseline, in other words, an
improvement of symptoms by 26% (mean change from baseline = -9.4+/-0.6; p = 0.004). The
treatment group’s score was statistically significant at day 30 relative to day one. Surprisingly,
the control had a 1.2+/-0.3 point decline (p=0.049), meaning that symptoms worsened by 4%.
This suggests that not having the treatment was powerful enough to overcome any placebo effect
that occurs when taking the treatment alone causes positive outcomes.3
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Table 5: Treatment Effect in Kangari et al (2013)3
Baseline Score
Day 30 Score
Omega-3 (n=31)
Placebo (n=33)

38.7+/-16.5
36.4+/-13.8

29.3+/-15.9
37.6+/-13.5

Mean change from baseline +/SEM (scale of 100)
-9.4+/-0.6 (p = 0.004)
+1.2+/-0.3 (p = 0.049)

This discussion pertains to 3 different RCT studies that each compared experimental
treatment by ω-3 (EPA & DHA) with placebos. Epitropoulos et al (2016) and Kangari et al
(2013) each evaluated a single type of omega-3, however, two different forms (krill and fish oil)
were assessed in Deinema et al (2017). Compliance was only assessed in Deinema et al (2017),
Epitropoulos et al (2016) by count of returned medication containers. Epitropoulos et al (2016)
sent daily medication remainders to their subjects via text, which most likely increased their
compliance and improved their data.
Each study took place at ophthalmology clinics in symptomatic patients having a history
of clinically diagnosed DES. Deinema et al (2017) was conducted in Melbourne, Australia using
mild-moderate DES patients. Epitropoulos et al (2016) recruited patients with stage 1 or 2 MGD
from various U.S. clinics. Kangari et al (2013) used a private clinic in Tehran, Iran. Outcomes
specific to race, diet and climate cannot be accounted for in this paper considering each study
was conducted on a different continent from the others.
Analysis of the OSDI scores from the treatment groups was compared to controls in each
of the three studies. In Deinema et al (2017), each treatment under investigation appeared to
show improvement but statistically only the outcome of krill oil was significant at 90 days. In
addition, both Epitropoulos et al (2016) and Kangari et al (2013) reported significant treatment
effect at 90 and 30 days, respectively. The former also reported worsening of symptoms for the
control suggesting a preventative effect by ω-3.
In Deinema et al (2017), the number of reported adverse events was used for assessment
of treatment safety. From this data, the risk of harm was calculated and reported in numbers
needed to harm (NNH). Formulas and calculations can be found in table 6. A NNH of 4 means
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that for every 4 people treated with fish oil (3 people for krill oil), one person has a bad event.
While 53 events were reported, 51 of the events were mild (well-tolerated), 2 were moderate
(interfered with activity) and none were severe (life-threatening). The most common were colds
(24.5%), sore throat (11.3%), headache (13.2%), GI events (nausea, bloating, heartburn; 11.3%)
and remaining 39.6% not associated with treatment. Ultimately, while side effects are noticeable,
omega-3 has low toxicity and remains a feasible treatment option.
Table 6: Adverse Events (NNH) of Treatment in Deinema et al (2017)
# of
events
Placeb
o, 17
Fish
Oil, 18
Krill
Oil, 15

CER (control event
rate) = events/total #
subjects

EER (experimental
event rate) =
events/total # subjects

RRI (relative risk
increase) = (EERCER)/CER

ARI (absolute risk
increase) = EERCER

NNH (numbers
needed to harm) =
1/ARI

20

1.2%

N/A

N/A

N/A

N/A

19

1.2%

1.0%

0.2%

0.2%

4

18

1.2%

0.8%

0.3%

0.5%

3

DISCUSSION
For many decades, the potential health benefits of ω-3 consumption have been the focus
of a multitude of scientific research areas. Despite speculation, omega-3 has not been associated
with a rate reduction in cardiovascular events,9 risk reduction in cancer5 nor in the prevention of
Alzheimer’s disease.5 It is however, approved in prescription for severe (≥500 mg/dL)
hypertriglyceridemia, serving as secondary prevention in coronary heart disease (CHD).9
Furthermore, investigation in depressive disorders continues.5,6 Ultimately, the exact role of
omega-3 on inflammatory processes in the human body must be further explored.
In Deinema et al (2017) and Epitropoulos et al (2016), subjects younger than 18 were
excluded, as they are unlikely to be affected so unlikely to seek treatment. However, Kangari et
al (2013) excluded patients under the age of 45, which means this study focused on an older
population who are more likely to be afflicted. 1,2,3 Meanwhile none of the studies allowed
participation by patients with ocular or systemic diseases that, compared to the general adult
population, are more prone to DES and more likely to present with it clinically.1,2,3
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Significant data from each of the studies was collected at a specified point in time during
ω-3 intervention. The most dramatic improvement in symptoms occurred at three months as in
Deinema et al (2017) with krill oil (18.6 point score reduction). This is compared to 3 months in
Epitropoulos et al (2016) with re-esterified ω-3 (17.0 point reduction), and one month in Kangari
et al (2013) with unspecified low-dose DHA/EPA (9.4 point reduction). Point reduction means
that symptoms improved and represents a positive outcome. The author’s decision to restrict
article selection to studies using OSDI may have placed data in favor of this hypothesis.
CONCLUSION
It can be concluded that daily ω-3 fatty acid supplementation is effective for reducing the
severity of dry eye syndrome in adults, especially those with mild-moderate disease, after 90
days of use. Based on the data presented in this paper, krill oil (>1500mg) offers the greatest
treatment effect but also causes the most side effects. Re-esterified formulas (2240mg) are the
second most effective. The longer the treatment, the better the symptoms. This is attributed to
the anti-inflammatory effect of ω-3 that has been demonstrated in prior studies.1,5 Ultimately,
daily ω-3 fatty acid supplementation has capacity to improve quality of life for DES patients.
While the type, the dose, and the duration of omega-3 treatment all influential the
outcome of treatment, however additional trials are needed to clarify which factor is most
important. Currently studies are being conducted to assess the treatment effect of ω-3 along with
ω-6 supplementation.1,2 Meanwhile, future studies are necessary to evaluate ω-3 in combination
with and in contrast to the first line therapies including Restasis and Xiidra. In addition, is also
important to compare the side effect profile of re-esterified oils to krill oils. Overall, a
multicenter clinical trial with an increased number of participants and longer treatment duration
must take place in order to assess the efficacy and safety of krill oil and re-esterified ω-3 fatty
acids long-term.
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